Trials / Terminated
TerminatedNCT02146833
SHIP (Selinexor in Hormone Insensitive Prostate Cancer)
A Phase-2, Open-Label Study of Oral Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Karyopharm Therapeutics Inc · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, Phase 2 clinical study of the oral Selective Inhibitor of Nuclear Export (SINE) selinexor (KPT-330) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Detailed description
This is a Phase 2, open-label study to explore the effect of selinexor (KPT-330) therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Approximately 50 patients are planned for enrollment. Patients will receive an oral dose of selinexor on one of three dosing schedules.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Selinexor | Comparison of different dosages and dosing schedules of drug. |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2016-04-01
- Completion
- 2016-04-01
- First posted
- 2014-05-26
- Last updated
- 2023-01-26
- Results posted
- 2021-01-26
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02146833. Inclusion in this directory is not an endorsement.